WORLD Law Direct Forums
Home > WORLD Law Direct Forums > FORUM INFORMATION > Law News > Abraxis to Appeal Jury Ruling on Elan Patent Infringement Claim

Abraxis to Appeal Jury Ruling on Elan Patent Infringement Claim

This is a discussion on Abraxis to Appeal Jury Ruling on Elan Patent Infringement Claim within the Law News forum, part of the FORUM INFORMATION category; Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, today announced that it intends to appeal the jury ruling ...

Consult Your Own Personal Lawyer Now!
Reply

 

Thread Tools Search this Thread Rate Thread Display Modes
Old Jun 14th, 2008, 07:35 AM   #1
Senior Member
 

Metropolitanjury's Avatar
 
Join Date: Jun 2008
Posts: 98

Default Abraxis to Appeal Jury Ruling on Elan Patent Infringement Claim

Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, today announced that it intends to appeal the jury ruling in the U.S. District Court for the District of Delaware that Abraxis has infringed upon a patent owned by Elan. In the suit, Elan claimed that Abraxis infringed upon two of Elan's patents, 5,834,025 and 5,399,363, asserting ABRAXANE(R: 68.53, +1.40, +2.08%) (pa****axel protein-bound particles for injectable suspension) (albumin-bound) uses technology protected by Elan-owned patents. Elan withdrew its claim that Abraxis infringed on its 025 patent. The jury ruled that Abraxis has infringed upon Elan's 363 patent, which runs until 2011, and awarded Elan $55 million in damages for sales of Abraxane(R: 68.53, +1.40, +2.08%) to date. The company said it is disappointed by the jury ruling in this complex patent litigation and feels confident as it proceeds to appeal in this matter. Abraxis will pursue post-trial motions and appeal the judgment of the District Court.

About ABRAXANE(R: 68.53, +1.40, +2.08%)

The U.S. Food and Drug Administration approved ABRAXANE(R: 68.53, +1.40, +2.08%) for Injectable Suspension (pa****axel protein-bound particles for injectable suspension) (albumin-bound) in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. For the full prescribing information for ABRAXANE(R: 68.53, +1.40, +2.08%) please visit Metastatic Breast Cancer Treatment Drug - ABRAXANE.

About Abraxis BioScience

Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company's portfolio includes the world's first and only protein-bound chemotherapeutic compound (ABRAXANE), which is based on the company's proprietary tumor targeting technology known as the nab(TM: 102.71, +1.90, +1.88%) platform. The first FDA approved product to use this nab(TM: 102.71, +1.90, +1.88%) platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer. Abraxis trades on the NASDAQ Global Market under the symbol ABII. For more information about the company and its products, please visit Abraxis BioScience Inc..

By Ms.Bobby Aanand, Metropolitan Jury.
Metropolitanjury is offline   Reply With Quote
Reply

Bookmark & Share



Thread Tools Search this Thread
Search this Thread:

Advanced Search
Display Modes Rate This Thread
Rate This Thread:

| More

Posting Rules
You may post new threads
You may post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Trackbacks are Off
Pingbacks are Off
Refbacks are Off

Format Your Messages
Add Forum to Google Toolbar
Forum Jump

Similar Threads

Thread Thread Starter Forum Replies Last Post
Google's AdWords: Nonbinding ruling finds no trademark infringement forum_admin Copyright, Trademark, Patent 2 Oct 5th, 2009 05:27 AM
Endo sues Impax for patent infringement Metropolitanjury Law News 0 Jul 29th, 2008 07:15 AM
Abraxis Appeals $55 Million Patent Infringement Judgment Metropolitanjury Law News 0 Jun 24th, 2008 07:37 AM
Appeal of small claim ruling oldredsky Small Claims Courts 2 Mar 21st, 2008 11:56 AM


Criminal law issues? Contact leading defense lawyers now! Free immediate consultation!


All times are GMT -4. The time now is 11:38 PM.